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Background: To ensure the suitability of an infant formula as the sole source of nutrition or provide benefits similar
to outcomes in breastfed infants, advancements in formula composition are warranted as more research detailing
the nutrient composition of human milk becomes available. This study was designed to evaluate growth and
tolerance in healthy infants who received one of two investigational cow’s milk-based formulas with adjustments in
carbohydrate, fat, and calcium content and supplemented with a prebiotic blend of polydextrose (PDX) and
galactooligosaccharides (GOS) or GOS alone.
Methods: In this multi-center, double-blind, parallel-designed, gender-stratified prospective study 419 infants were
randomized and consumed either a marketed routine cow’s milk-based infant formula (Control; EnfamilW LIPILW,
Mead Johnson Nutrition, Evansville, IN) (n = 142) or one of two investigational formulas from 14 to 120 days of age.
Investigational formulas were supplemented with 4 g/L (1:1 ratio) of a prebiotic blend of PDX and GOS (PDX/GOS;
n = 139) or 4 g/L of GOS alone (GOS; n = 138). Anthropometric measurements were taken at 14, 30, 60, 90, and
120 days of age. Daily recall of formula intake, tolerance, and stool characteristics was collected during study weeks
1 and 2 and 24-h recall was collected at 60, 90, and 120 days of age. Medically-confirmed adverse events were
recorded throughout the study.
Results: There were no group differences in growth rate from 14 to 120 days of age. Discontinuation rates were
not significantly different among study groups. No differences in formula intake or infant fussiness or gassiness
were observed. During study weeks 1 and 2 and at 60 days of age stool consistency ratings were higher (i.e. softer
stools) for infants in the PDX/GOS and GOS groups versus Control and remained higher at 120 days for the PDX/
GOS group (all P< 0.05). The overall incidence of medically-confirmed adverse events was similar among groups.
Conclusions: Investigational routine infant formulas supplemented with 4 g/L of either a prebiotic blend of PDX
and GOS or GOS alone were well-tolerated and supported normal growth. Compared to infants who received the
unsupplemented control formula, infants who received prebiotic supplementation experienced a softer stooling
pattern similar to that reported in breastfed infants.
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To ensure the suitability of an infant formula as the sole
source of nutrition or provide benefits similar to out-
comes in breastfed infant populations [1], adjustments in
level of fat (including levels of long-chain polyunsatur-
ated fatty acids, or LCPUFAs), protein, carbohydrate,
vitamins and minerals, iron, electrolytes, or other op-
tional ingredients may be warranted as the composition
of human milk is better defined. In particular, human
milk oligosaccharides (HMOs) [2,3] are the third largest
component of human milk (5–10 g/L in mature milk)
after lactose and fat [4] and comprise a class of carbohy-
drates considered to be bifidogenic. HMOs modulate the
infant immune system as well as influence the develop-
ment of the intestinal microbiota [5]. Prebiotics share
functional attributes with HMOs and are defined as “a
selectively fermented ingredient that allows specific
changes, both in the composition and/or activity in the
gastrointestinal microbiota that confers benefits upon
host well-being and health [6].” These beneficial effects
include but are not limited to the following: a) increased
beneficial bacteria (e.g. bifidobacteria); b) decreased
pathogenic bacteria; and c) an improved laxation pattern
(e.g. softer stools) [7-11].
In healthy term infants, we previously demonstrated
that a cow’s milk-based infant formula supplemented
with a new prebiotic blend of polydextrose (PDX) and
galactooligosaccharides (GOS) (1:1 ratio at a level of
4 g/L) was well-tolerated, supported normal growth,
promoted a stool consistency closer to that of breastfed
infants, [9] and produced soft stools and a bifidogenic
effect closer to breast milk when compared to infants
fed an unsupplemented formula [12] indicating that the
PDX and GOS blend meets the European Society for
Paediatric Gastroenterology Hepatology and Nutrition
(ESPGHAN) and the Food and Agriculture Organization
of the United Nations (FAO) definition of a prebiotic
(ie., confers a health benefit on the host associated with
modulation of the microbiota) [13,14]. In the present
study, we evaluated the effect of infant formulas with
adjustments in fat, carbohydrate, and calcium compos-
ition as well as supplementation with 4 g/L of the pre-
biotic blend of PDX and GOS or GOS alone on overall
growth and tolerance in healthy term infants from 14 to
120 days of age.
Methods
Study population
Healthy 12- to 16-day old infants were recruited at 21
clinical sites in the United States. Eligible infants were
singleton births at 37–42 weeks gestational age with birth
weight ≥ 2500 g and solely formula-fed at least 24 h prior
to randomization. Exclusion criteria included history of
underlying disease or congenital malformation likely tointerfere with normal growth and development or par-
ticipant evaluation; feeding difficulties or formula intoler-
ance; weight at randomization <98% of birth weight;
large for gestational age (defined as birth weight-for-age
exceeding 90th percentile [15,16] born from a mother
who was diabetic at childbirth; and immunodeficiency.
Study design
In this multicenter, double-blind, randomized, controlled,
parallel-group, prospective trial, participants were enrolled
between July 2008 and April 2009. The objective was to
evaluate growth and tolerance in healthy, term infants.
The study sponsor created a computer-generated, gender-
stratified randomization schedule provided in sealed
consecutively-numbered envelopes for each study site.
Study formula was assigned by opening the next sequen-
tial envelope from the appropriate set at the study site.
Study formulas, each designated by two unique codes
known only to the sponsor, were dispensed to parents at
each study visit prior to completion or withdrawal. Nei-
ther the product labels nor the sealed envelopes allowed
direct unblinding by the study site. Personnel responsible
for monitoring the study were also blinded to study prod-
uct identification. Blinding for a participant could be
broken by study sponsor personnel in the event of a med-
ical emergency in which knowledge of the study formula
was critical to the participant’s management. In this study,
it was not necessary to break the study code prematurely.
Participants were randomly assigned to receive a mar-
keted routine cow’s milk-based infant formula (Control;
Enfamil LIPIL, Mead Johnson Nutrition, Evansville, IN)
or one of two investigational formulas from 14 to
120 days of age. All study formulas were provided in
powdered form and could not be differentiated by smell,
consistency or any other characteristics; identical mixing
instructions were provided to yield a final product of 20
calories/fluid ounce. All study formulas were supplemen-
ted with docosahexaenoic acid (DHA) at 17 mg/100 kcal.
The investigational formulas differed from the Control in
total fat, total carbohydrate, level of arachidonic acid
(ARA), and calcium source (Table 1). Investigational for-
mulas were also supplemented with 4 g/L (1:1 ratio) of a
blend of PDX (LitesseW Two Polydextrose; Danisco) and
GOS (VivinalW GOS Galactooligosaccharide; Friesland
Foods Domo) (PDX/GOS) or 4 g/L of GOS alone (GOS).
Ethics
Parents or guardians provided written informed consent
prior to enrollment. The research protocol and informed
consent forms observing the Declaration of Helsinki (in-
cluding October 1996 amendment) were approved by
the institutional review board/ethics committee of each
participating institution. The study complied with good
clinical practices.
Table 1 Nutrient composition per 100 kcal
Nutrient Study Formula (target values)
Control PDX/GOS* GOS†
Total Protein, g{ 2.1 2.1 2.1
Total Fat, g} 5.3 5.6 5.6
Linoleic acid, mg 860 900 900
α-Linolenic acid, mg 85 85 85
ARA, mg 34 25 25
DHA, mg 17 17 17
Total Carbohydrate, g|| 10.9 10.6 10.6
Vitamin A, IU 300 300 300
Vitamin D, IU 60 60 60
Vitamin E, IU 2 2 2
Vitamin K, mcg 9 9 9
Thiamin, mcg 80 80 80
Riboflavin, mcg 140 140 140
Vitamin B6, mcg 60 60 60
Vitamin B12, mcg 0.3 0.3 0.3
Niacin, mcg 1000 1000 1000
Folic Acid, mcg 16 16 16
Pantothenic Acid, mcg 500 500 500
Biotin, mcg 3 3 3
Vitamin C, mg 12 12 12
Choline, mg 24 24 24
Inositol, mg 6 6 6
Calcium, mg} 78 78 78
Phosphorus, mg 43 43 43
Magnesium, mg 8 8 8
Iron, mg 1.8 1.8 1.8
Zinc, mg 1 1 1
Manganese, mcg 15 15 15
Copper, mcg 75 75 75
Iodine, mcg 15 15 15
Selenium, mcg 2.8 2.8 2.8
Sodium, mg 27 27 27
Potassium, mg 108 108 108
Chloride, mg 63 63 63
* Supplemented with prebiotic blend of PDX and GOS at 4 g/L.
† Supplemented with GOS at 4 g/L.
{ Sources of protein: non-fat dry milk and whey protein concentrate.
}Sources of fat: base blend of palm olein, soybean, coconut, and high oleic
sunflower oils; DHA from algal oil and ARA from fungal oil.
||Sources of carbohydrate: Control, 10.9 g lactose; PDX/GOS, 10.0 g lactose and
0.6 g prebiotic oligosaccharides; GOS, 10.0 g lactose and 0.6 g prebiotic
oligosaccharides.
}Sources of calcium: In all study formulas, 66% of calcium was derived from
non-fat dry milk and whey protein concentrate. In the Control, the remaining
34% was derived from calcium carbonate. In both the PDX/GOS and GOS, the
remaining 34% was derived from calcium gluconate.
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Anthropometric measures (body weight, length, and
head circumference) were recorded at study visits corre-
sponding to enrollment (14 ± 2 days), 30 (±3 days), 60
(±3 days), 90 (±3 days), and 120 (±4 days) days of age.
Parents completed a baseline 24-h recall of intake (fluid
oz/day), tolerance (fussiness and gassiness), and stool
characteristics (frequency and consistency) at study en-
rollment and daily recall was obtained during the initial
14 days of the study (study weeks 1 and 2) beginning the
evening of study randomization. A 24-h recall of diet, tol-
erance, and stool characteristics was collected at 60, 90,
and 120 days of age. Responses were scaled from 0 to 3
for amount of gas (none, slight amount, moderate
amount, excessive amount); 0 to 4 for fussiness (not
fussy, slightly fussy, moderately fussy, very fussy, ex-
tremely fussy); and 1 to 5 for stool consistency (hard,
formed, soft, unformed or seedy, watery). The primary
outcome was weight growth rate from 14 to 120 days of
age. Secondary outcomes included other anthropometric
and tolerance measures and medically-confirmed adverse
events. Adverse events were coded according to specific
event (e.g. otitis media, colic, etc.) and the body system
involved including: Body as a Whole; Cardiovascular;
Eye, Ears, Nose, and Throat; Gastrointestinal; Metabolic
and Nutrition; Musculoskeletal; Respiratory; Skin; and
Urogenital.
Statistical methods
The sample size was chosen to detect a clinically relevant
difference of 3 g/day in weight gain from 14 to 120 days
of age (80% power; one-tailed). Assuming a standard de-
viation of 6 g/day for male and 5 g/day for female partici-
pants, approximately 78 males and 55 females were
needed to enroll in each group with the expectation that
51 male and 36 female participants per study group
would complete the study. Analysis of variance
(ANOVA) was used to assess growth rates from 14 to 30,
60, 90, or 120 days of age calculated by fitting a linear re-
gression model to each participant's data. The dependent
variable was the growth measurement; the independent
variable was the actual days of age of the participant. The
slope from the linear model was the growth rate. Mean
weight growth rates by gender for each investigational
formula group were compared with the control using
one-tailed tests as outlined in guidance provided by the
American Academy of Pediatrics (AAP) Task Force on
Clinical Testing of Infant Formulas [17]. Due to differ-
ences detected in body weight for males at enrollment,
“body weight at enrollment” was included as a covariate
for both males and females in the statistical model to
analyze weight growth rate. For all secondary outcomes,
overall comparisons for the three formula groups were
two-tailed. Unadjusted pairwise comparisons were
Table 2 Infant characteristics at study entry
Study Group
Control PDX/GOS GOS
Total number of participants 142 139 138
Number of males/females 80/62 79/60 82/56
males*
Weight (g) 3784.1 ± 47.0 3798.9 ± 47.3 3648.4 ± 46.4†
Length (cm) 52.7 ± 0.2 53.0 ± 0.2 52.6 ± 0.2
Head circumference (cm) 36.4 ± 0.1 36.4 ± 0.1 36.2 ± 0.1
females*
Weight (g) 3598.5 ± 53.9 3603.2 ± 54.8 3582.3 ± 56.7
Length (cm) 52.1 ± 0.2 52.2 ± 0.2 51.8 ± 0.3
Head circumference (cm) 35.7 ± 0.1 35.9 ± 0.1 35.6 ± 0.2
* Mean± standard error (SE).
† Significantly lower vs. Control or PDX/GOS, P< 0.05.
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All tests were conducted at α= 0.05. Achieved weight,
length, and head circumference; length and head circum-
ference growth rates; formula intake, and stool frequency
were analyzed by ANOVA. Stool consistency, fussiness,
and gas were analyzed using the Cochran-Mantel-
Haenszel (CMH) row means score test. Incidence of ad-
verse events was analyzed using Fisher’s exact test. To be
included in analysis of a specific outcome at each mea-
sured time point, participant data was required to beControl 
   males, n = 81
females, n = 63
Completed 
   males, n = 62
females, n = 38
Discontin
Formula-related 
males, n = 12; fem
Not formula-relate
males, n = 13; fem
Discontinued
Formula-related 
males, n = 9; females, n = 11 
Not formula-related 
males, n = 9; females, n = 13 
Control 
   males, n = 80
females, n = 62
Did not consume study formula 
   males, n = 1 
females, n = 1 
Did not consume st
   males, n 
females, n 
Figure 1 Flow of study participants.collected within a specific range, usually ±7 days of the
study visit. All analyses were conducted using SAS ver-
sion 9.1 (Cary, NC).Results
Participants
A total of 426 participants were enrolled and rando-
mized (Control: 144; PDX/GOS: 142; GOS: 140). Partici-
pants who were randomized but consumed no study
formula (Control: 2; PDX/GOS: 3; GOS: 2) were not
included in subsequent analyses (Figure 1). The popula-
tion analyzed was comprised of all infants randomized
to one of the study formulas who received at least one
feeding. No differences in body weight, length, or head
circumference were observed by gender among groups
at study enrollment with the exception of body weight
in males (Table 2). Birth anthropometric measures as
well as gender, race, and ethnic distribution were also
similar among groups (data not shown). No statistically
significant group differences were detected for study dis-
continuation (Control: 42, 30%; PDX/GOS: 42, 30%;
GOS: 48, 35%) or discontinuation related to study for-
mula (Control: 20, 14%; PDX/GOS: 21, 15%; GOS: 19,
14%). In the total study population, 53 participants
(13%) discontinued due to formula intolerance as deter-
mined by the study investigator; the most common
symptoms were fussiness (Control: 13; PDX/GOS: 10;GOS 
   males, n = 82
females, n = 58
Completed 
   males, n = 51
females, n = 39
GOS 
   males, n = 82
females, n = 56
Participants randomized
   males, n = 244 
females, n = 182 
PDX/GOS 
   males, n = 81
females, n = 61
Completed 
   males, n = 54
females, n = 43
Discontinued
Formula-related 
males, n = 13; females, n = 6 
Not formula-related 
males, n = 18; females, n = 11
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ales, n = 8 
PDX/GOS 
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Did not consume study formula
   males, n = 0 
females, n = 2 
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vomiting (Control: 7; PDX/GOS: 3; GOS: 9). Parental
decision was the most common reason for discontinu-
ation unrelated to study formula (56 participants, 13%).
A total of 287 infants completed the study (Control: 100;
PDX/GOS: 97; GOS: 90).Growth
From day 14 to 30 weight growth rate was significantly
lower for males in the PDX/GOS vs. Control group and
for females in the GOS vs. Control group (P< 0.05;
Table 3). However, no other significant differences were
observed for weight, length, or head circumference growth
rates by gender for any age range among study groups. In
addition, no significant group differences were observed
for mean achieved weight, length, or head circumference
at any measured time point. Finally, mean achieved weight
for males (Figure 2) and females (Figure 3) plotted on theTable 3 Weight, length, and head circumference growth rates
Gender Day Group (n)
W
(g
male 30 Control (74) 48
PDX/GOS (68) 45
GOS (68) 46
60 Control (66) 41
PDX/GOS (59) 41
GOS (60) 41
90 Control (62) 36
PDX/GOS (55) 37
GOS (52) 36
120 Control (63) 32
PDX/GOS (54) 34
GOS (50) 33
female 30 Control (52) 38
PDX/GOS (50) 34
GOS (49) 34
60 Control (43) 32
PDX/GOS (44) 32
GOS (42) 32
90 Control (40) 29
PDX/GOS (43) 29
GOS (38) 29
120 Control (38) 27
PDX/GOS (44) 27
GOS (39) 27
* Mean± standard error (SE).
† Adjusted for body weight at enrollment.
{ Significantly lower than Control, P< 0.05, one-tailed test.WHO weight-for-age standard growth chart [18,19] fell
between the 25th and 75th percentiles.
Tolerance
At enrollment, parent-reported gassiness and fussiness
(data not shown) and stool characteristics (Table 4) were
similar among groups. No significant group differences in
gassiness, fussiness, or study formula intake were detected
during study weeks 1 or 2, or at 60, 90, or 120 days of age.
For the initial two weeks of feeding, means for amount of
gas were low (≤1.6, between slight amount and moderate
amount of gas on the gassiness scale) and mean levels of
fussiness were also low (≤1.6, between slightly fussy and
moderately fussy on the fussiness scale) in all groups.
Using 24-hour recall at 60, 90, and 120 days of age,
amount of gas most commonly reported was slight
amount or moderate amount and fussiness was most often
characterized as slightly fussy or not at all fussy in all








.9 ± 1.5 0.15 ± 0.009 0.10 ± 0.005
.2 ± 1.5{ 0.15 ± 0.009 0.10 ± 0.005
.7 ± 1.6 0.13 ± 0.009 0.10 ± 0.005
.3 ± 1.1 0.13 ± 0.004 0.08 ± 0.002
.4 ± 1.2 0.13 ± 0.004 0.07 ± 0.002
.9 ± 1.2 0.13 ± 0.004 0.07 ± 0.002
.1 ± 1.0 0.12 ± 0.003 0.07 ± 0.002
.4 ± 1.0 0.12 ± 0.003 0.06 ± 0.002
.8 ± 1.1 0.12 ± 0.003 0.06 ± 0.002
.6 ± 0.8 0.11 ± 0.002 0.06 ± 0.001
.0 ± 0.9 0.11 ± 0.002 0.06 ± 0.001
.3 ± 0.9 0.11 ± 0.002 0.06 ± 0.001
.4 ± 1.5 0.15 ± 0.012 0.09 ± 0.006
.9 ± 1.6 0.12 ± 0.012 0.08 ± 0.007
.6 ± 1.6{ 0.11 ± 0.012 0.09 ± 0.007
.4 ± 1.2 0.12 ± 0.005 0.07 ± 0.003
.1 ± 1.2 0.12 ± 0.005 0.06 ± 0.003
.2 ± 1.3 0.12 ± 0.006 0.07 ± 0.003
.0 ± 1.0 0.11 ± 0.003 0.06 ± 0.002
.7 ± 0.9 0.11 ± 0.003 0.05 ± 0.002
.3 ± 1.0 0.11 ± 0.003 0.06 ± 0.002
.6 ± 0.9 0.10 ± 0.003 0.05 ± 0.002
.9 ± 0.8 0.10 ± 0.002 0.05 ± 0.001
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Figure 2 Mean achieved weight for male participants with World Health Organization (WHO) reference percentiles (1st to 99th) from 14

































0 30 60 90 120 150
Figure 3 Mean achieved weight for female participants with World Health Organization (WHO) reference percentiles (1st to 99th) from
14 to 120 days of age. Control, stars; PDX/GOS, circles; GOS, diamonds.
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Table 4 Stool characteristics at 14 (enrollment), 60, 90, and 120 days of age
Age Stool frequency Stool consistency, n (%)
Group (n) Mean (±SE)* Overall P hard formed soft unformed or
seedy
watery Overall P
14 days Control (142) 2.6±0.2 0.074 4 (3) 6 (4) 88 (63) 40 (29) 2 (1) 0.526
PDX/GOS (139) 3.0±0.2 5 (4) 10 (8) 66 (51) 44 (34) 5 (4)
GOS (138) 3.1±0.2 2 (2) 9 (7) 73 (55) 5 (4) 6 (5)
60 days Control (102) 2.0±0.1 0.002†{ 2 (2) 13 (13) 76 (75) 9 (9) 1 (1) <0.001†{
PDX/GOS (101) 2.6±0.2 1 (1) 6 (6) 57 (56) 30 (30) 7 (7)
GOS (96) 2.6±0.2 0 (0) 7 (7) 64 (67) 21 (22) 3 (3)
90 days Control (99) 2.0±0.1 0.083 0 (0) 14 (14) 70 (71) 11 (11) 3 (3) 0.089
PDX/GOS (97) 2.3±0.1 1 (1) 6 (6) 61 (66) 21 (23) 4 (4)
GOS (87) 2.4±0.1 0 (0) 6 (7) 64 (73) 15 (17) 3 (3)
120 days Control (97) 2.0±0.1 0.265 2 (2) 11 (12) 71 (76) 9 (10) 1 (1) 0.004†
PDX/GOS (95) 2.3±0.1 0 (0) 5 (5) 63 (68) 17 (18) 7 (8)
GOS (87) 2.2±0.1 2 (2) 7 (8) 59 (70) 13 (15) 3 (4)
* Mean ± standard error (SE) stool frequency. Means for 14, 60, 90, and 120 days are based on 24-hour recall at study visits.
†Control vs. PDX/GOS significantly different (P< 0.05).
{Control vs. GOS significantly different (P< 0.05).
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GOS groups during study week 1 (2.2±0.2 vs 3.7±0.2 or
3.9±0.2; all P< 0.05) and study week 2 (2.2±0.2 vs 3.6±0.2
or 3.7±0.2; all P< 0.05). This pattern continued through
60 days of age, but by 90 days of age, no statistical differ-
ences in stool frequency were detected between study
groups (Table 4). Mean (±SE) stool consistency (with cat-
egories corresponding to 1= hard, 2 = formed, 3 = soft,
4 = unformed or seedy, 5 =watery) was significantly lower
in the Control versus PDX/GOS or GOS groups during
study week 1 (3.1±0.0 vs 3.4±0.0 or 3.3±0.0; all P< 0.05)
and study week 2 (3.0±0.1 vs 3.4±0.1 or 3.2±0.1; all
P< 0.05). Stool consistency was also significantly lower
in the GOS vs PDX/GOS group during study week 2
(P< 0.05). At 60 days, the distribution of stool consistency
was significantly different between Control and PDX/GOS
or GOS groups (Table 4; all P< 0.05). In stool consistency
categories, the primary differences were more infants with
a formed (13%) or soft (75%) and fewer infants with an
unformed or seedy stool consistency (9%) in the Control
group compared to PDX/GOS (formed, 6%; soft, 56%; un-
formed or seedy, 30%) and GOS groups (formed, 7%; soft,
67%; unformed or seedy, 22%). No significant group differ-
ences were detected at 90 days. At 120 days, again a sig-
nificant difference in the distribution of stool consistency
was detected between the Control and PDX/GOS groups
(P< 0.05). The primary differences were a higher percent-
age of infants in the Control versus the PDX/GOS group
with a formed (12% vs 5%) or soft (76% vs 68%) stool
consistency and lower percentage with unformed or seedy
(10% vs 18%) stool consistency.
No group difference was detected in the number of
participants for whom at least one medically-confirmedadverse event was reported (Control: 109, 78%; PDX/
GOS: 97, 70%; GOS: 106; 77%). The incidence of adverse
events categorized within Body as a Whole, Cardiovascu-
lar, Metabolic and Nutrition, Musculoskeletal, or Uro-
genital systems were generally low with no statistically
significant group differences for specific events. Within
the Eyes, Ears, Nose, and Throat system, the overall inci-
dence of adverse events (Control: 43, 31%; PDX/GOS:
27, 19%; GOS: 43; 31%) was significantly lower in the
PDX/GOS group versus either the Control or GOS groups
(P< 0.05), however there were no significant differences
between specific types of adverse events within this cat-
egory. Within the Gastrointestinal (GI) System, the most
commonly reported specific adverse events were gastroe-
sophageal (GE) reflux, gas, emesis, and diarrhea. There
were no group differences in the incidence of GE reflux,
emesis, or diarrhea, however the incidence of gas (Control:
16, 11%; PDX/GOS: 4, 3%; GOS: 10, 7%) was significantly
lower in the PDX/GOS versus the Control group
(P< 0.05). Also within the GI System category, excessive
spitting (Control: 0, 0%; PDX/GOS: 2, 1%; GOS: 7, 5%)
was significantly lower in the Control versus the GOS
group (P< 0.05). Within the Respiratory category, no sig-
nificant group differences were detected for specific ad-
verse events. Any medically-confirmed adverse event was
considered serious if it met one or more of the following
criteria: resulted in death, was life-threatening, required
inpatient hospitalization or prolongation of existing
hospitalization, resulted in persistent or significant disabil-
ity/incapacity, or was a congenital anomaly/birth defect. A
total of 21 participants experienced serious adverse events
(Control: 7, 5%; PDX/GOS: 4, 3%; GOS: 10, 7%). All ser-
ious adverse events were individually evaluated by the
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lated to study formulas.
Discussion
This study demonstrated that routine cow’s milk-based
formulas supplemented with either a prebiotic blend of
PDX and GOS or GOS alone were safe and well-tolerated
when fed to healthy term infants from 14 to 120 days of
age. Investigational formulas were also associated with
normal growth throughout the study. The few differences
detected between the control and investigational formula
groups in body weight growth rates for males and females
occurred only in the day 14 to 30 age range and were not
accompanied by any statistically significant differences in
length or head circumference growth rates. At 14 days all
group means were between the 25th and 50th reference
percentiles of the WHO weight growth chart. By 30 days
all group means were near or above the 50th percentile
and remained above the 50th percentile for the remainder
of the study. In addition, there were no group differences
detected for length or head circumference growth rates,
weight growth rate within any other age range, or
achieved values at any measured study time point. We
have previously demonstrated that supplementation of
PDX and GOS to routine, cow’s milk-based formula is well
tolerated, safe, and promotes normal growth [9,12,20].
Each investigational study formula also included
adjustments in total fat, total carbohydrate, level of ARA,
and calcium source. The investigational formulas derived
approximately 50% of total calories from fat (compared
to 48% in the control, or 5.6 vs 5.3 g fat/100 kcal), in con-
junction with a compensatory reduction in carbohydrates
to approach the level and caloric contribution of fat typ-
ically found in human milk, which provides 50-60% of
total calories and is not usually related to maternal diet-
ary differences [21]. As expected, this slight adjustment
in total fat did not result in differences in overall growth.
In addition, DHA and ARA are the primary LCPUFAs
found in human milk and both are always present in
human milk, albeit at various concentrations and ratios
[21-23]. Supplementation of both DHA and ARA (at
~0.3% and ~0.6% of total fat, respectively) to infant for-
mulas based on previously published values for world-
wide human milk [24,25] has been associated with visual
and cognitive development in term infants [26-31] and
enhanced growth and neural development in preterm
infants [32,33]. A recent comprehensive, critical review
of literature published on breast milk levels of DHA and
ARA provided updated worldwide means for DHA at
0.32% (SD 0.21%; median 0.26%; mode 0.20%) and ARA
at 0.47% (SD 0.13%; median 0.45%; mode 0.50%) of total
fatty acids [23]. Consequently, we evaluated effects of
the adjusted level of ARA supplementation to infant for-
mula upon growth and safety. Finally, whereas all studyformulas provided a final available calcium concentra-
tion of 78 mg/100 kcal, the success and safety of calcium
gluconate used as one of several calcium sources in pow-
dered preterm human milk fortifier [34] allowed us to
evaluate this ingredient as the sole source of supplemen-
tal calcium within the matrix of a routine infant formula
for growth and safety in term infants.
Overall, acceptance and tolerance of study formulas
were good. No differences in study discontinuation due
to study formula were detected. No differences in over-
all study discontinuation were detected and study dis-
continuation rates were as expected when compared to
those reported in other large pediatric nutrition trials
[35,36]. No significant differences were detected in
fussiness or gassiness among study groups. Mean stool
frequency was significantly lower in the Control versus
either the PDX/GOS or GOS groups during study
weeks 1 and 2 and at 60 days but no group differences
were observed at 90 or 120 days. In this study, some
significant differences in mean stool consistency were
noted among groups during study weeks 1 and 2 and in
stool consistency at days 60 and 120. Mean stool
consistency was in the soft range for all study groups
during study weeks 1 and 2, and the majority of infants
in all groups at all measured time points were reported
to have a soft stool consistency. However, more infants
with formed stool consistency and fewer with unformed
or seedy stool consistency were typically reported in the
Control compared to the PDX/GOS or GOS groups.
The stool softening effect demonstrated with the blend
of PDX and GOS or GOS alone may potentially help
manage hard stools that could affect formula-fed infants
[37]. In general, softer, looser stools are characteristic of
both breastfed infants and infants who receive formula
supplemented with prebiotics when compared to those
who receive unsupplemented formulas [11,38,39]. In
healthy, term infants we previously reported that use of
routine formulas supplemented with PDX and GOS
produced a bifidogenic effect closer to breast milk com-
pared to formula without PDX and GOS [12]. The
current results are also consistent with our previous
reports in which use of routine formulas supplemented
with PDX and GOS produced softer stools in healthy,
term infants compared to formula without PDX and
GOS [9,12,20].
Conclusion
Although breast milk is the ideal source of nutrition for
infants, advancements in infant formula research are ne-
cessary to provide the best possible alternative for
infants that cannot receive human milk. In this study,
routine infant formula with adjustments in fat, carbohy-
drate, and calcium composition and supplemented with
4 g/L of either the prebiotic blend of PDX and GOS or
Ashley et al. Nutrition Journal 2012, 11:38 Page 9 of 10
http://www.nutritionj.com/content/11/1/38GOS alone was well-tolerated and supported normal
growth. Compared to infants who received the unsup-
plemented control formula, infants who received pre-
biotic supplementation experienced a softer stooling
pattern similar to that reported in breastfed infants.
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